---
title: "Terra Innovatum Global N.V. 1Q 2026: Net income $(7.11M), EPS $(0.06) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291398392.md"
description: "Terra Innovatum Global N.V. reported a widened Q1 2026 net loss of $7.106M ($0.06 EPS) versus $1.448M in Q1 2025, remaining pre-revenue. The company completed the SOLO micro-modular reactor design and initiated NRC regulatory engagement, targeting commercial deployment by 2028. No revenue is expected before then due to ongoing R&D and regulatory hurdles."
datetime: "2026-07-01T10:11:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291398392.md)
  - [en](https://longbridge.com/en/news/291398392.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291398392.md)
---

# Terra Innovatum Global N.V. 1Q 2026: Net income $(7.11M), EPS $(0.06) — 10-Q Summary

Terra Innovatum Global N.V. reported a widened first-quarter 2026 loss, remaining pre-revenue as it advances development and regulatory engagement for its SOLO micro‑modular reactor. The company recorded a net loss of $(7.106M) and diluted loss per share of $(0.06) for Q1 2026 versus a $(1.448M) loss and $(0.03) diluted loss per share in Q1 2025; the company has not reported product revenue for the period.

**Financial Highlights**

-   Net income: $(7.106M) for Q1 2026, versus $(1.448M) in Q1 2025 (loss widened by $5.658M YoY).
-   Diluted earnings per share: $(0.06) for Q1 2026, versus $(0.03) in Q1 2025 (loss per share doubled YoY).
-   Revenue: Not reported for Q1 2026 (company remains pre‑revenue; no product sales).

**Business Highlights**

-   Product development: SOLO micro‑modular reactor design is complete for component fabrication, with the company targeting a first-of-a-kind (FOAK) licensing and commercial deployment by 2028.
-   Operations and regulatory progress: Initiated regulatory engagement with the Nuclear Regulatory Commission (NRC) and validated key components as part of development milestones.
-   Commercial preparation: Established European assembly preparations and a global supply‑chain strategy to support future deployment.
-   Revenue outlook: No product revenue yet; meaningful commercialization and revenue are not expected before 2028 and remain dependent on regulatory approvals and execution.
-   Risks: The company notes limited cash runway despite recent PIPE/closing proceeds and highlights ongoing R&D, regulatory and supply‑chain execution risks to advancing commercialization.

Original SEC Filing: Terra Innovatum Global N.V. \[ NKLR \] - 10-Q - Jun. 30, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [NKLR.US](https://longbridge.com/en/quote/NKLR.US.md)

## Related News & Research

- [Terra Innovatum seeks NRC preapplication readiness review for SOLO reactor permit filing](https://longbridge.com/en/news/293613546.md)
- [Nano Nuclear wins AFWERX SBIR Phase I contract for KRONOS microreactor system](https://longbridge.com/en/news/293928032.md)
- [How Rockwell’s Aalo-X Nuclear Control Deal Could Shape the Long-Term Narrative for ROK Investors](https://longbridge.com/en/news/293952034.md)
- [Baxter Q2 2026 Earnings Preview](https://longbridge.com/en/news/294224876.md)
- [Ciena's Q3 2026 Earnings: What to Expect](https://longbridge.com/en/news/293952665.md)